These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7881137)

  • 21. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
    Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P
    J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction between orally administered tyramine and moclobemide.
    Zimmer R; Puech AJ; Philipp F; Korn A
    Acta Psychiatr Scand Suppl; 1990; 360():78-80. PubMed ID: 2248083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine.
    Antal EJ; Hendershot PE; Batts DH; Sheu WP; Hopkins NK; Donaldson KM
    J Clin Pharmacol; 2001 May; 41(5):552-62. PubMed ID: 11361052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to oral tyramine in man.
    Martini A; Bonollo L; Nicolis FB; Sega R; Palermo A
    Br J Clin Pharmacol; 1981 Jun; 11(6):611-5. PubMed ID: 7272178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.
    Pickar D; Cohen RM; Jimerson DC; Murphy DL
    Psychopharmacology (Berl); 1981; 74(1):4-7. PubMed ID: 6791202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1993; 16 Suppl 2():S34-41. PubMed ID: 8313395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
    Kerecsen L; Bunag RD
    J Pharmacol Exp Ther; 1989 Nov; 251(2):645-9. PubMed ID: 2509682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029).
    Di Stefano AF; Radicioni MM; Rusca A
    Neurotox Res; 2013 May; 23(4):315-26. PubMed ID: 22872464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microsomal enzymes and potentiation of tyramine pressor response.
    Renton KW; Eade NR
    Biochem Pharmacol; 1972 May; 21(10):1393-402. PubMed ID: 5029421
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
    Bieck PR; Antonin KH
    J Clin Psychopharmacol; 1988 Aug; 8(4):237-45. PubMed ID: 3209716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase.
    Dollery CT; Brown MJ; Davies DS; Lewis PJ; Strolin-Benedetti M
    Clin Pharmacol Ther; 1983 Nov; 34(5):651-62. PubMed ID: 6627826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
    Marwood JF; Huston V; Wall KT
    Clin Exp Pharmacol Physiol; 1985; 12(2):161-8. PubMed ID: 3839173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dichloromethane fraction of Areca catechu nut on monoamines associated behaviors and tyramine pressor sensitivity in rodents.
    Khan S; Abbas G; Ahmed FS; Rahman A; Dar A
    Pak J Pharm Sci; 2014 Mar; 27(2):303-7. PubMed ID: 24577919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyramine pressor test: implications and limitations.
    Ghose K
    Methods Find Exp Clin Pharmacol; 1984 Aug; 6(8):455-64. PubMed ID: 6492942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to intravenous tyramine in man.
    Martini A; Bonollo L; Nicolis FB; Sega R; Palermo A; Braibanti E
    Br J Clin Pharmacol; 1981 Jun; 11(6):605-10. PubMed ID: 7272177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.